DiaMedica Therapeutics (DMAC) Short-term Investments (2019 - 2026)

DiaMedica Therapeutics has reported Short-term Investments for 8 years, with the latest figure at $46.5 million in Q1 2026.

• For the quarter ending Q1 2026, Short-term Investments rose 37.75% year-over-year to $46.5 million; the trailing twelve-month figure through Mar 2026 stood at $46.5 million (up 37.75% YoY), and the FY2025 full-year result was $44.2 million, up 7.59% from the prior year.
• Short-term Investments for Q1 2026 stood at $46.5 million, up from $44.2 million in the prior quarter.
• The five-year high for Short-term Investments was $52.0 million in Q3 2025, with the low at $9000.0 in Q3 2022.
• Historically, Short-term Investments has averaged $35.0 million across 5 years, with a median of $40.0 million in 2024.
• Annual changes were most pronounced in 2022 — Short-term Investments plunged 99.97% — and 2023, when it jumped 491377.78%.
• DiaMedica Therapeutics' Short-term Investments stood at $28.8 million in 2022, then soared by 68.04% to $48.4 million in 2023, then decreased by 14.95% to $41.1 million in 2024, then increased by 7.59% to $44.2 million in 2025, then increased by 5.02% to $46.5 million in 2026.
• The last three Short-term Investments figures came in at $46.5 million (Q1 2026), $44.2 million (Q4 2025), and $52.0 million (Q3 2025), per Business Quant data.